please find enclosed Annual Report
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech has submitted its Annual Report for FY 2024-25 along with the Notice of its 38th Annual General Meeting, scheduled for September 30, 2025, at 3:00 PM via video conferencing. E-voting facility will be available to members. For the year, the company reported revenue of around ₹51.48 crore, EBITDA of ₹15.91 crore, and net profit of ₹2.20 crore, with results boosted by a one-time ₹4.62 crore gain from sale of land. The company is a pre-clinical contract research organisation (CRO) with a 53-acre GLP-compliant facility in Hyderabad, serving pharma, biotech, agrochemical, and medical device clients. A notable highlight is a breakthrough ₹10.5 crore data generation contract with an agro-chemical company under Section 9.3, which management describes as a potential game-changer.
Routine regulatory filing for shareholders to review ahead of the AGM. The annual report reveals flat to declining core profitability (lower EBITDA and net profit YoY), though the new ₹10.5 crore contract and one-time land sale gain could support near-term sentiment. Investors should focus on whether the breakthrough contract translates into sustained revenue growth in FY26.